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improvement in 2-year overall survival, suggesting TRT should 
be considered for all patients with ES-SCLC who respond to 
chemotherapy. An additional analysis showed that in patients 
with a response but residual disease after chemotherapy, the 
difference in 1-year survival was significantly better after 
TRT (Lancet 2015,385,1292-3). We carried out a European 
survey to determine the impact of the publication on clinical 
practice. 
 
Material and Methods: In May 2015 an electronic 
questionnaire of 34 items was composed using Select Survey 
software designed for running online surveys. Questions 
covered the use of TRT before and after the CREST study, 
evaluated the current practice of prophylactic cranial 
irradiation (PCI), including dose and fractionation, and asked 
whether practice was restricted based on performance status 
(PS) and age. The survey was distributed by email to one 
thoracic clinical/radiation oncologist per centre in 7 
European countries. A reminder was sent to non-responders. 
 
Results: This European-wide survey received 95 complete 
responses (UK n=42, Belgium n=23, Netherlands n=14, France 
n=8, Switzerland n=5, Germany n=2, Poland n=1). A response 
rate of 74% was achieved within the UK. Before the 
publication of the CREST study only 25% of centres were 
giving TRT routinely to patients who had responded to 
chemotherapy, compared to the current practice of 81%. 
Currently the preferred dose and fractionation of TRT is 30 
Gy in 10 fractions in 70% of centres, however a wide variety 
of fractionations were used before the CREST publication. An 
upper limit of PS ECOG 2 is commonly applied to TRT (83 %). 
In the 18 centres (19%) not implementing TRT there were a 
wide variety of explanations with no single reason standing 
out. Regarding the practice of PCI in ES-SCLC, 96% of centres 
give PCI routinely if patients have responded to 
chemotherapy. Of these, 52% deliver 25Gy in 10 fractions and 
44% deliver 20Gy in 5 fractions. An upper age limit was 
applied in 76% of all centres, the most common age limit 
being 75 (60 %). An upper limit for PS was applied in 88% of 
all centres, most commonly ECOG 2. 
 
Conclusion: Following the publication of the CREST study 
there has been a dramatic increase in the use of TRT in 
patients with ES-SCLC who have responded to chemotherapy. 
The dose and fractionation schedule used in the study has 
widely been adopted as standard practice across Europe. 
There is also evidence of high consistency in European 
practice in the use of PCI in patients with ES-SCLC. 
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Purpose or Objective: To compare acute skin toxicity 
between prone whole-breast irradiation (WBI) with a 
sequential boost (SeqB) and a simultaneous integrated boost 
(SIB). 
 
Materials and Methods: 167 patients were randomized 
between WBI with a SeqB or a SIB. 150 patients were treated 
at Ghent University Hospital (UZ Gent) and 17 at Liège 
University Hospital. All patients were treated in prone 
position to 40.05 Gy in 15 fractions to the whole breast. In 
the SeqB arm a median dose of 10 Gy in 4 fractions (negative 
surgical margins) or 14.88 Gy in 6 fractions (transsection) was 
prescribed to the PTV_boost (CTV to PTV margin of 5 mm). In 
the SIB arm a median dose of 46.8 or 49.95 Gy (negative and 
positive surgical margins, respectively) was prescribed to the 
CTV_boost with dose decay to 40.05 Gy in the first 2 cm 
around the CTV_boost. In the SeqB arm dose parameters 
were calculated on the summed plan (WBI + boost). For 
comparison, a PTV_optim was created including the PTV for 
WBI more than 2 cm away from the CTV_boost as illustrated 
in Figure 1.  
 
 
 
Dermatitis was scored using the Common Toxicity Criteria for 
Adverse Events (CTCAE). Desquamation was scored as: none, 
dry or moist; pruritus as absent or present.  
 
Results: The analysis of dose parameters was done on 146 
patients treated at UZ Gent. Reasons for excluding patients 
were electron boost (2), 3 different plans on 3 different CTs 
(1) and changed treatment arm due to machine breakdown 
(1). This latter patient was excluded from the toxicity 
analysis as well. Patient age was the only significantly 
different parameter between treatment arms (mean age 59.6 
± 11.0 vs 55.7 ± 10.4 years, p=0.0210). Dose coverage of the 
CTV_boost was slightly better in the control arm (D95 of 98 ± 
1% vs 97 ± 2%, p<0.01). The volume of the PTV_optim and the 
skin receiving more than 105% of the prescription dose were 
significantly higher in the SeqB-arm than in the SIB-arm (27 ± 
20% vs 9 ± 6% for the PTV_optim and 394 ± 216cc vs 201 ± 
125cc for the skin, both p<0.01).In both arms, 6/83 patients 
developed moist desquamation (primary endpoint). Grade 
2/3 dermatitis was significantly more frequent in the SeqB 
arm (38/83 vs 24/83 patients, p=0.037). In the SIB and SeqB 
arm, respectively, 36 and 51 patients developed pruritus 
(p=0.015). The incidence of edema was lower in the SIB arm 
(59 vs 68 patients), but not statistically significant (p=0.071). 
 
Conclusion: Acute toxicity is not increased using a SIB in 
prone hypofractionated WBI. In contrast, grade 2/3 
dermatitis and pruritus are significantly less frequent. With 
our SIB-technique, high dose regions outside the boost region 
are smaller than with a SeqB. 
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